DK2585098T3 - Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser - Google Patents
Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelserInfo
- Publication number
- DK2585098T3 DK2585098T3 DK11730818.9T DK11730818T DK2585098T3 DK 2585098 T3 DK2585098 T3 DK 2585098T3 DK 11730818 T DK11730818 T DK 11730818T DK 2585098 T3 DK2585098 T3 DK 2585098T3
- Authority
- DK
- Denmark
- Prior art keywords
- fzd8
- obesity
- extracellular
- domains
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35921410P | 2010-06-28 | 2010-06-28 | |
PCT/US2011/042033 WO2012006027A1 (en) | 2010-06-28 | 2011-06-27 | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2585098T3 true DK2585098T3 (da) | 2014-11-03 |
Family
ID=44588169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11730818.9T DK2585098T3 (da) | 2010-06-28 | 2011-06-27 | Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser |
Country Status (5)
Country | Link |
---|---|
US (1) | US8431532B2 (da) |
EP (1) | EP2585098B1 (da) |
DK (1) | DK2585098T3 (da) |
HK (1) | HK1182312A1 (da) |
WO (1) | WO2012006027A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE025908T2 (en) | 2005-10-31 | 2016-04-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP2769729B1 (en) | 2007-09-04 | 2019-01-09 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
KR101711672B1 (ko) | 2008-09-26 | 2017-03-03 | 온코메드 파마슈티칼스, 인크. | 프리즐드 결합 작용제 및 그의 용도 |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
MX347515B (es) | 2010-04-01 | 2017-04-28 | Oncomed Pharmaceuticals Inc * | Agentes que se unen al receptor encrespado y usos de los mismos. |
AU2012277376B2 (en) | 2011-06-30 | 2016-11-24 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
SG2014008304A (en) | 2012-02-01 | 2014-06-27 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer |
JP2015536933A (ja) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法 |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
KR102162676B1 (ko) * | 2013-12-26 | 2020-10-07 | 인텔 코포레이션 | 상보형 터널링 fet 디바이스와 그 형성 방법 |
US10535770B2 (en) * | 2014-09-24 | 2020-01-14 | Intel Corporation | Scaled TFET transistor formed using nanowire with surface termination |
JP7094223B2 (ja) * | 2016-04-25 | 2022-07-01 | ファイブ プライム セラピューティクス, インコーポレイテッド | 病的な筋肉減少および筋力低下の処置のためのnope |
JP2020529845A (ja) * | 2017-08-01 | 2020-10-15 | アンカサ リジェネレイティブ セラピューティクス,インク. | Wnt組成物および無血清培養条件からの処理の方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
GB9819681D0 (en) | 1998-09-09 | 1998-11-04 | Smithkline Beecham Plc | Novel compounds |
CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
GB0221952D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Forschungsstiftung | Wnt mediated ErbB1 signalling,compositions and uses related thereto |
CA2501235A1 (en) | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
AU2004256425A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
JP2008528033A (ja) | 2005-01-27 | 2008-07-31 | ファイブ プライム セラピューティクス, インコーポレイテッド | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
WO2006130076A1 (en) | 2005-05-30 | 2006-12-07 | Astrazeneca Ab | Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis |
WO2007030290A2 (en) * | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
HUE025908T2 (en) | 2005-10-31 | 2016-04-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
PE20120806A1 (es) * | 2006-09-08 | 2012-07-25 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
KR101711672B1 (ko) | 2008-09-26 | 2017-03-03 | 온코메드 파마슈티칼스, 인크. | 프리즐드 결합 작용제 및 그의 용도 |
WO2010062401A2 (en) * | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
TWI535445B (zh) * | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
-
2011
- 2011-06-27 US US13/169,900 patent/US8431532B2/en not_active Expired - Fee Related
- 2011-06-27 EP EP11730818.9A patent/EP2585098B1/en not_active Not-in-force
- 2011-06-27 DK DK11730818.9T patent/DK2585098T3/da active
- 2011-06-27 WO PCT/US2011/042033 patent/WO2012006027A1/en active Application Filing
-
2013
- 2013-08-16 HK HK13109606.2A patent/HK1182312A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20120003222A1 (en) | 2012-01-05 |
WO2012006027A1 (en) | 2012-01-12 |
EP2585098B1 (en) | 2014-08-27 |
US8431532B2 (en) | 2013-04-30 |
EP2585098A1 (en) | 2013-05-01 |
HK1182312A1 (en) | 2013-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2585098T3 (da) | Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser | |
DK3878859T5 (da) | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse | |
DK2480574T3 (da) | Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme | |
DK2240135T3 (da) | Apparat til behandling af fedme og reflukssygdom | |
HK1177470A1 (en) | Antibody molecules having specificity for human ox40 ox40 | |
DK3351558T3 (da) | Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme | |
EP2774616A4 (en) | APPLICATION OF ROSEBURIA IN THE TREATMENT AND PREVENTION OF OBESITY-RELATED DISEASES | |
DK2435432T6 (da) | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme | |
DK2507211T3 (da) | Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme | |
DK2511264T3 (da) | Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme | |
DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
DK2525777T3 (da) | Materiale og fremgangsmåde til at behandle interne hulrum | |
DK2464773T3 (da) | Fremgangsmåde til binding af glasfiber og glasfiberprodukt | |
DK3187587T3 (da) | Modulære DNA-bindingsdomæner og fremgangsmåder til anvendelse | |
BRPI0917130A2 (pt) | biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados | |
DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
DK2344146T3 (da) | Anticonnexin-midler til anvendelse til modulering af psykotrope molekylers terapeutiske virkning | |
DK2750551T3 (da) | Ortopædisk stol til behandling og forebyggelse af rygmarvslidelser | |
IL232334A0 (en) | Modulators of the G protein-coupled mas receptor and the treatment of related disorders | |
AP2013006985A0 (en) | Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders | |
DK2456544T3 (da) | Fremgangsmåde til fjernelse af gasformig væske og indretning dertil | |
DK2310003T3 (da) | Inhibitorer af Carnitin-Palmitoyl-Transferase-1 til behandling og forebyggelse af lidelser forårsaget af delipidering af neuralt væv | |
DK2549995T3 (da) | Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin | |
EP2890370A4 (en) | AGENTS USEFUL FOR THE TREATMENT OF OBESITY, DIABETES AND RELATED DISORDERS | |
HK1173457A1 (zh) | 蛋白晶體和交聯晶體及其使用方法 |